A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...
Experts expressed enthusiasm Friday after US health regulators approved the first new form of treatment for schizophrenia in ...
U.S. FDA Approves Bristol Myers Squibb’s COBENFY, a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults ...
New schizophrenia treatment Cobenfy approved by US regulators, offering hope for millions with fewer side effects.
The U.S. Food and Drug Administration has approved a new drug for adults with schizophrenia, the FDA announced Thursday.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback